Report Type
Publication date
Published Date
  • Company Profile

    $295 | April 2023
    Company Profile

    TP ICAP Group plc – Company Profile

    TP ICAP Group plc (TP ICAP) is a global brokerage and information company. Its offerings comprise treasury, credit research, equities, alternative investments, energy and commodities, global currencies, tpMobile, and electronic markets platform. The company provides risk management services, daily activity summary, tpSEF information, tpMatch, and ad tpMatch inflation. The company operates through a hybrid business model where brokers offer business-critical intelligence to clients, supplemented by proprietary screens that provide historical data, analytics, and execution functionality. It offers proprietary over-the-counter pricing...

    Add to Basket
  • Product Insights

    $500 | November 2022
    Product Insights

    Likelihood of Approval and Phase Transition Success Rate Model – nimacimab

    Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry nimacimab Drug Details Nimacimab (RYI-018) is under development for the treatment of liver fibrosis...

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.